Login to Your Account



FDA Questions Efficacy, Safety of Boehringer Female Sex Pill

By Donna Young


Thursday, June 17, 2010

No Abstract

 

Washington Editor

 

WASHINGTON - Boehringer Ingelheim GmbH's experimental drug flibanserin, a postsynaptic 5-HT1A agonist and 5-HT2A antagonist, failed to significantly improve a woman's sexual desire in Phase III testing, FDA drug reviewers said.

The studies, however, had demonstrated a statistically significant improvement over placebo in sexually satisfying experiences in women taking the investigational medicine, which has been called "female Viagra."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription